Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
Ferreri
Andres J M
AJ
Medical Oncology Unit, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. andres.ferreri@hsr.it
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D017730:Ki-1 Antigen / Q000276:immunology; D015394:Molecular Structure; D009101:Multiple Myeloma / Q000188:drug therapy; D011719:Pyrazines / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001897:Boronic Acids; D017730:Ki-1 Antigen; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib